Rocket Pharmaceuticals Q4 EPS $(0.64) Beats $(0.79) Estimate
Portfolio Pulse from Happy Mohamed
Rocket Pharmaceuticals (NASDAQ:RCKT) reported Q4 losses of $(0.64) per share, surpassing the analyst consensus estimate of $(0.79) by 18.99%. This represents a 30.43% improvement over the previous year's losses of $(0.92) per share.
February 26, 2024 | 9:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Rocket Pharmaceuticals reported a smaller than expected Q4 loss, showing significant improvement over the previous year.
Beating the EPS estimate and showing year-over-year improvement in losses is a positive signal to investors, likely leading to a positive short-term impact on RCKT's stock price. The significant beat and improvement indicate operational efficiency and could boost investor confidence.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100